Toxin from tobacco smoke could increase pain in spinal cord injury

(Press-News.org) WEST LAFAYETTE, Ind. - A neurotoxin called acrolein found in tobacco smoke that is thought to increase pain in people with spinal cord injury has now been shown to accumulate in mice exposed to the equivalent of 12 cigarettes daily over a short time period. One implication is that if acrolein is exacerbating pain its concentration in the body could be reduced using the drug hydralazine, which has been approved by the U.S. Food and Drug Administration for hypertension, said Riyi Shi (pronounced Ree Shee), a professor in Purdue University's Department of Basic Medical Sciences, College of Veterinary Medicine, and Weldon School of Biomedical Engineering. The drug has been shown to be effective in reducing acrolein levels in research animals, and Shi is working to develop a low-dose version for that purpose in humans. Mice were exposed to a level of acrolein equivalent to 12 cigarettes per day over three weeks. Previous research has focused on acrolein accumulation in the respiratory system but not in the bloodstream and spinal cord. It is known that acrolein is accumulated in urine in human smokers after years of smoking. "This is the first animal study demonstrating that an cute short term of weeks of smoking could also cause acrolein to accumulate in urine and more importantly in spinal cord tissue, a part of central nervous system known to be vulnerable to acrolein, he said. The researchers documented the concentration of biochemical markers for acrolein in the urine and spinal cord. Findings, appearing this week in the journal Neuroscience Bulletin, indicate the accumulation of the toxin was about 50 percent higher than normal, a level known to have pathological implications. "The data indicated that acrolein is absorbed into the circulatory system and some enters the nervous system," Shi said. "It is expected that these findings may facilitate further studies to probe the pathological role of acrolein in the nervous system resulting from smoke and other external sources through long and short term, both active and passive exposure." The research paper was authored by Melissa Tully, a graduate student at Purdue and the Indiana University School of Medicine; Purdue graduate students Lingxing Zheng, Glen Acosta, and Ran Tian; and Shi. Acrolein is produced within the body after nerve cells are damaged. In spinal cord injury and in multiple sclerosis, the myelin insulation surrounding nerve cells is destroyed and the nerve fibers themselves are damaged by acrolein. The toxin acrolein also is found in air pollutants including tobacco smoke and auto exhaust. "It is already known that smoking can increase pain for people with spinal cord injury and worsen the condition of multiple sclerosis, but we don't know exactly why," Shi said. "I am saying that acrolein might be the key culprit here and that inhaled acrolein could intensify multiple sclerosis and increase pain sensation."

INFORMATION:

The research is ongoing and was funded by the Indiana State Department of Health, the National Institutes of Health, and an Indiana CTSI CBR/CTR Pilot Program Grant.

Writer: Emil Venere, 765-494-4709, venere@purdue.edu

Source: Riyi Shi, 765-496-3018, riyi@purdue.edu

PHOTO CAPTION: Riyi Shi A publication-quality image is available at http://news.uns.purdue.edu/images/2014/shi-r14.jpg

ABSTRACT Acute systemic accumulation of acrolein in mice by inhalation at a concentration similar to that in cigarette smoke Melissa Tully2,3,*, Lingxing Zheng1,2,*, Glen Acosta1, Ran Tian1,2, Riyi Shi1,2 1- Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University 2-Weldon School of Biomedical Engineering, Purdue University 3-Indiana University School of Medicine Corresponding author: Riyi Shi. E-mail: riyi@purdue.edu Cigarette smoke is an important environmental factor associated with a wide array of public health concerns. Acrolein, a component of tobacco smoke and a known toxin to various cell types, may be a key pathological factor mediating the adverse effects linked with tobacco smoke. Although acrolein is known to accumulate in the respiratory system after acute nasal exposure, it is not clear if it accumulates systemically, and less is known in the nervous system. The aim of this study was to assess the degree of acrolein accumulation in the circulation and in the spinal cord following acute acrolein inhalation in mice. Using a laboratory-fabricated inhalation chamber, we found elevated urinary 3-HPMA, an acrolein metabolite, and increased acrolein adducts in the spinal cord after weeks of nasal exposure to acrolein at a concentration similar to that in tobacco smoke. The data indicated that acrolein is absorbed into the circulatory system and some enters the nervous system. It is expected that these findings may facilitate further studies to probe the pathological role of acrolein in the nervous system resulting from smoke and other external sources.